Naproxen Bp Milpharm

Naproxen, the active ingredient in Naproxen Bp Milpharm, is a nonsteroidal anti-inflammatory drug (NSAID) presented as an oral dosage form for systemic use. It is used to relieve pain, reduce inflammation and lower fever in adults.\n\nGNH India supplies Naproxen Bp Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naproxen is an NSAID that acts on inflammatory pathways to provide symptom relief in several musculoskeletal and febrile conditions.\n\nPain: Provides analgesic relief for mild to moderate acute or chronic pain.\nInflammation: Reduces swelling and tissue inflammation associated with musculoskeletal disorders.\nFever: Lowers elevated body temperature in febrile states.\nOsteoarthritis: Improves joint function and decreases pain in degenerative joint disease.\nRheumatoid arthritis: Helps control pain and inflammation in autoimmune joint disease.

Adverse reactions may range from mild to severe and should be monitored during therapy.\n\nCommon Side Effects:\n- Gastrointestinal upset or dyspepsia\n- Nausea or vomiting\n- Headache\n- Dizziness\n- Mild skin rash\n\nSerious or Rare Side Effects:\n- Gastrointestinal bleeding or ulcer perforation\n- Cardiovascular events such as myocardial infarction or stroke\n- Acute renal impairment or failure\n- Severe skin reactions (e.g., Stevens‑Johnson syndrome)\n- Hepatic dysfunction or elevated liver enzymes

Before initiating naproxen therapy, consider patient‑specific risk factors and monitor for adverse events.\n\nAssess gastrointestinal risk: evaluate history of ulcers or bleeding.\nMonitor renal function: check creatinine and electrolytes in at‑risk patients.\nEvaluate cardiovascular risk: use lowest effective dose in patients with heart disease.\nAvoid in known hypersensitivity: discontinue if allergic reactions occur.\nStore at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Naproxen can alter the pharmacodynamics or pharmacokinetics of several co‑administered medicines.\n\nMajor Interactions (Avoid):\n- Anticoagulants (e.g., warfarin): increased bleeding risk.\n- Other NSAIDs or aspirin: additive gastrointestinal toxicity.\n- Selective serotonin reuptake inhibitors (SSRIs): heightened risk of GI hemorrhage.\n\nModerate Interactions (Monitor Closely):\n- ACE inhibitors or ARBs: possible reduction in antihypertensive effect and renal function.\n- Diuretics: may potentiate renal impairment, especially in volume‑depleted patients.